Volume | 70,165 |
|
|||||
News | - | ||||||
Day High | 1.88 | Low High |
|||||
Day Low | 1.80 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Alaunos Therapeutics Inc | TCRT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.85 | 1.80 | 1.88 | 1.81 | 1.86 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
572 | 70,165 | US$ 1.84 | US$ 129,133 | - | 0.66 - 10.50 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:57:08 | 5 | US$ 1.88 | USD |
Alaunos Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
29.36M | 16.04M | - | 2.92M | -37.73M | -2.35 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alaunos Therapeutics News
Date | Time | Source | News Article |
---|---|---|---|
2/28/2024 | 20:46 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
2/22/2024 | 15:44 | Edgar (US Regulatory) | Form 8-K - Current report |
2/20/2024 | 15:05 | Edgar (US Regulatory) | Form 8-K - Current report |
2/14/2024 | 11:43 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
2/13/2024 | 15:58 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
1/29/2024 | 07:45 | Edgar (US Regulatory) | Form 8-K - Current report |
1/23/2024 | 16:47 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
1/22/2024 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
1/03/2024 | 16:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
1/03/2024 | 16:25 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of.. |
1/02/2024 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
12/28/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TCRT Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.77 | 2.03 | 1.76 | 1.90 | 59,617 | 0.04 | 2.26% |
1 Month | 2.32 | 2.32 | 1.51 | 1.88 | 64,761 | -0.51 | -21.98% |
3 Months | 1.26 | 3.285 | 1.20 | 2.19 | 2,434,130 | 0.55 | 43.65% |
6 Months | 1.95 | 3.285 | 0.66 | 1.39 | 3,867,664 | -0.14 | -7.18% |
1 Year | 10.50 | 10.50 | 0.66 | 2.05 | 2,578,200 | -8.69 | -82.76% |
3 Years | 12.99 | 60.15 | 0.66 | 10.99 | 2,511,197 | -11.18 | -86.07% |
5 Years | 12.99 | 60.15 | 0.66 | 10.99 | 2,511,197 | -11.18 | -86.07% |
Alaunos Therapeutics Description
Ziopharm Oncology Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Ziopharm Oncology Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Ziopharm Oncology Inc. ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad. |